MET has been implicated in such resistance in multiple preclinical models, and, in a pancreatic neuroendocrine tumor model, combined inhibition of VEGFR and MET results in enhanced efficacy over inhibition of either pathway alone [15–18]. The gene discussed is MET; the disease is pancreatic neuroendocrine tumor.